The Joint Commission and American Heart Association Announce New Certification to Encourage Exemplary Care in Heart Failure

2009 ◽  
Vol 11 (4) ◽  
pp. 199
Author(s):  
&NA;
Stroke ◽  
2015 ◽  
Vol 46 (suppl_1) ◽  
Author(s):  
William Pajerowski ◽  
Steven R Messe ◽  
Judy Jia ◽  
Michael Abboud ◽  
Guy David ◽  
...  

Objective: In December 2003, the Joint Commission began certifying primary stroke centers (PSCs). Preferential routing of suspected stroke cases by Emergency Medical Services (EMS) to PSCs is recommended by the American Heart Association and Philadelphia EMS officially enacted such a policy in October 2011. We assessed trends in hospital bypass over time and estimated the time cost of bypassing the nearest hospital. Methods: Data from the Philadelphia EMS database was used to identify patients with a prehospital impression of stroke, defined by EMS provider impression, between January 2004 and December 2013. PSC status and date of initial certification was determined for each of the 22 hospitals in the region. Travel distances and estimated transport times from the scene to all area hospitals were calculated. Results: The number of PSCs increased over time from 1 hospital in 2004 to 17 in 2013. There were a total of 15,034 cases. The proportion of cases arriving at PSCs increased from 6.3% in 2004 to 87.6% in 2013. There was an increase in the total proportion of cases in which EMS bypassed the closest hospital, 36.9% in 2004 to 41.4% in 2013, p=.006. As more hospitals became PSCs, bypass of the closest hospital to arrive at non-PSCs decreased while bypass of the closest hospital to arrive at PSCs increased (Figure 1). Hospitals that would eventually become certified as PSCs received 79.8% of stroke cases in 2004 and 87.6% in 2013, p<.001. Patients who bypassed the closest hospital for a PSC had longer mean transport times than patients transported to the closest, non-PSC, 9.0 vs. 5.0 minutes, p<0.001. Conclusions: EMS bypass of the closest hospital was common before there was an official destination policy and has only modestly increased over the study period. Increasing numbers of patients were treated at PSCs over time, primarily due to increasing numbers of PSCs.


Author(s):  
Hidehiro Kaneko ◽  
Yuichiro Yano ◽  
Hidetaka Itoh ◽  
Kojiro Morita ◽  
Hiroyuki Kiriyama ◽  
...  

Background: Heart failure (HF) and atrial fibrillation (AF) are growing in prevalence worldwide. Few studies have assessed to what extent stage 1 hypertension in the 2017 American College of Cardiology (ACC)/American Heart Association (AHA) blood pressure (BP) guidelines is associated with incident HF and AF. Methods: Analyses were conducted using a nationwide health claims database collected in the JMDC Claims Database between 2005 and 2018 (n=2,196,437; mean age, 44.0±10.9 years; 584% men). No participants were taking antihypertensive medication or had a known history of cardiovascular disease. Each participant was categorized as having normal BP (systolic BP [SBP]<120 mm Hg and diastolic BP [DBP]<80 mm Hg; n=1,155,885); elevated BP (SBP 120-129 mm Hg and DBP<80 mm Hg; n=337,390); stage 1 hypertension (SBP 130-139 mm Hg or DBP 80-89 mm Hg; n=459,820); or stage 2 hypertension (SBP≥140 mm Hg or DBP≥90 mm Hg; n=243,342). Using Cox proportional hazards models, we identified associations between BP groups and HF/AF events. We also calculated the population attributable fractions (PAFs) to estimate the proportion of HF and AF events that would be preventable if participants with stage 1 and stage 2 hypertension were to have normal BP. Results: Over a mean follow-up of 1,112±854 days, 28,056 incident HF and 7,774 incident AF events occurred. After multivariable adjustment, hazard ratios for HF and AF events were 1.10 (95% Confidence interval [CI], 1.05-1.15) and 1.07 (95% CI, 0.99-1.17), respectively, for elevated BP; 1.30 (95% CI, 1.26-1.35) and 1.21 (95% CI, 1.13-1.29), respectively, for stage 1 hypertension; and 2.05 (95% CI, 1.97-2.13) and 1.52 (95% CI, 1.41-1.64), respectively, for stage 2 hypertension vs normal BP. PAFs for HF associated with stage 1 and stage 2 hypertension were 23.2% (95% CI, 20.3%-26.0%) and 51.2% (95% CI, 49.2%-53.1%), respectively. The PAFs for AF associated with stage 1 and stage 2 hypertension were 17.4% (95% CI, 11.5%-22.9%) and 34.3% (95% CI, 29.1%-39.2%), respectively. Conclusions: Both stage 1 and stage 2 hypertension were associated with a greater incidence of HF and AF in the general population. The ACC/AHA BP classification system may help identify adults at higher risk for HF and AF events.


Author(s):  
Sharon Cresci ◽  
Naveen L. Pereira ◽  
Ferhaan Ahmad ◽  
Mirnela Byku ◽  
Lisa de las Fuentes ◽  
...  

One of 5 people will develop heart failure over his or her lifetime. Early diagnosis and better understanding of the pathophysiology of this disease are critical to optimal treatment. The “omics”—genomics, pharmacogenomics, epigenomics, proteomics, metabolomics, and microbiomics— of heart failure represent rapidly expanding fields of science that have, to date, not been integrated into a single body of work. The goals of this statement are to provide a comprehensive overview of the current state of these omics as they relate to the development and progression of heart failure and to consider the current and potential future applications of these data for precision medicine with respect to prevention, diagnosis, and therapy.


Sign in / Sign up

Export Citation Format

Share Document